Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PureTech HealthCHIX:PRTCL -3.03%63 Days Sales Outstanding is 136.79 as of Dec. 2025, which is 16% above its 10-year median of 118.17. GuruFocus rates CHIX:PRTCL with a GF Score™ of 63/100 and a GF Value™ of £5.49 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, PureTech Health ranks worse than 83.71% on this metric.
The historical rank and industry rank for PureTech Health's Days Sales Outstanding or its related term are showing as below:
CHIX:PRTCl'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 27.6 Med: 118.17 Max: 3576.14
Current: 152.84
During the past 13 years, PureTech Health's highest Days Sales Outstanding was 3576.14. The lowest was 27.60. And the median was 118.17.
CHIX:PRTCl's Days Sales Outstanding is ranked worse than 83.71% of 841
companies
in the Biotechnology industry
Industry Median: 68.94
vs CHIX:PRTCl: 152.84
PureTech Health's Days Sales Outstanding
increased
from Dec. 2024 (75.37) to Dec. 2025 (136.79).
PureTech Health (CHIX:PRTCl) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
PureTech Health Days Sales Outstanding Related Terms
PureTech Health Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for PureTech Health's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PRTCL vs VRTX, REGN, MRNA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, PureTech Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where PureTech Health's Days Sales Outstanding falls into.
PureTech Health Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 136.79 mean?
PureTech Health (CHIX:PRTCL) has a Days Sales Outstanding of 136.79 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PureTech Health and its competitors. This is 16% above median its historical median of 118.17. Over the past decade, PureTech Health's Days Sales Outstanding has ranged from 27.60 to 3,576.14. According to the industry distribution chart, PureTech Health ranks #704 out of 841 companies in the Biotechnology industry, placing it in the top 83.7%.
Is PureTech Health's Days Sales Outstanding too high?
PureTech Health's current Days Sales Outstanding of 136.79 is 16% above median its 10-year median of 118.17. Over the past 10 years, this metric has ranged from a low of 27.60 to a high of 3,576.14. The Biotechnology industry median Days Sales Outstanding is 68.94. PureTech Health's value of 136.79 is 98.4% above this industry median. Based on the distribution chart, PureTech Health ranks #704 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PureTech Health has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Days Sales Outstanding compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #704 out of 841 companies for Days Sales Outstanding. This places PureTech Health in the lower half of its industry. The industry median Days Sales Outstanding is 68.94. PureTech Health's value of 136.79 is 98.4% above this benchmark. Historically, PureTech Health's own Days Sales Outstanding has ranged from 27.60 to 3,576.14 over the past decade. While the company's 10-year median is 118.17 vs. the industry median of 68.94, PureTech Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Days Sales Outstanding of 136.79 is 98.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Days Sales Outstanding is 136.79, which is 16% above median its own 10-year median of 118.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (CHIX:PRTCL) is currently considered Possible Value Trap. The stock's GF Value™ is £5.49, compared to a current price of £1.22 — trading 77.8% below its estimated fair value. The current Days Sales Outstanding is 136.79, which is 16% above median its 10-year median of 118.17 and 98.4% above the Biotechnology industry median of 68.94. PureTech Health's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For PureTech Health (CHIX:PRTCL), the current Days Sales Outstanding is 136.79 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (CHIX:PRTCL) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.22 is trading 77.8% below its estimated GF Value™ of £5.49.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for CHIX:PRTCL:
Days Sales Outstanding: 136.79 (16% above median its 10-year median of 118.17)
GF Value™: £5.49 vs. price of £1.22 (77.8% below fair value)
Industry Position: 98.4% above the Biotechnology median (#704 of 841)
No single metric tells the full story. See the CHIX:PRTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
63GF Score
Get the complete analysis for CHIX:PRTCL
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRTCL has been successfully added to your 
